Related Experiment Video
Updated: Sep 26, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use
Anita Palepu1, Mark Tyndall, Benita Yip
1Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Insights
Current injection drug users with HIV show poorer viral suppression on highly active antiretroviral therapy (HAART) compared to non-users. Adherence measures may be unreliable for active users, impacting treatment effectiveness.
Area of Science:
- Virology
- Public Health
- Infectious Diseases
Background:
- Highly active antiretroviral therapy (HAART) is crucial for managing HIV/AIDS.
- Injection drug use is a significant factor influencing health outcomes in HIV-infected individuals.
- Understanding treatment response disparities is vital for optimizing HIV care.
Purpose of the Study:
- To compare virologic response to HAART among HIV-infected individuals based on injection drug use activity.
- To investigate the impact of current, former, and non-injection drug use on HIV-1 RNA suppression.
- To examine the interaction between drug use and adherence in predicting HAART efficacy.
Main Methods:
- A population-based study of antiretroviral therapy-naive HIV-infected participants in British Columbia.
- Classification of participants into current, former, or non-injection drug users.
- Logistic regression analysis adjusted for baseline viral load, HAART regimen, therapy duration, adherence, and age.
Main Results:
- Current injection drug users were significantly less likely to achieve HIV-1 RNA suppression (AOR=0.30) compared to non-drug users.
- Former injection drug users did not show a statistically significant difference in suppression rates (AOR=0.56).
- Adherence was positively associated with suppression in former and non-drug users, but not in current users, indicating a potential issue with adherence measurement.
Conclusions:
- Current injection drug use is associated with reduced virologic response to HAART.
- Pharmacy refill compliance may not be a reliable adherence measure for active injection drug users.
- Tailored adherence support and treatment strategies are needed for HIV-infected injection drug users.
Abstract:
Injection drug users who continue to use drugs may not respond to highly active antiretroviral therapy (HAART) as well as other HIV-infected individuals, even after adjusting for a reliable measure of adherence. We therefore compared the virologic response among participants in a population-based HIV/AIDS Drug Treatment Program in British Columbia, Canada, by injection drug use activity. Participants who were HIV infected and naive to antiretroviral therapy and who were prescribed antiretroviral treatment between August 1996 and December 2000 were eligible for this study. They were classified as current, former, or non-injection drug users. The main outcome was having two consecutive HIV-1 RNA levels less than 500 copies/mL. We used logistic regression to adjust for baseline HIV-1 RNA, type of antiretroviral regimen (2 nucleosides + nonnucleoside reverse transcriptase inhibitor versus 2 nucleosides + protease inhibitor), duration of therapy (months), adherence (derived from refill compliance data), and age. A total of 578 participants were first prescribed HAART during the study period. Among them, 78 (13%) were current injection drug users, 96 (17%) were former injection drug users, and 404 (70%) never injected drugs. In the multivariable logistic regression, relative to non-drug users, current injection drug users were significantly less likely to suppress their HIV-1 RNA (adjusted OR [AOR] = 0.30, 95% CI: 0.13-0.67), and former injection drug users were not significantly different from non-drug users (AOR = 0.56, 95% CI: 0.24-1.34). There was a significant interaction between drug use and adherence. In the analyses stratified by drug use, the adherence of former and non-drug users was positively associated with HIV-1 RNA suppression (AOR = 1.33, 95% CI: 1.14-1.55), whereas for current drug users, it was not (AOR = 1.07, 95% CI: 0.87-1.33). Current injection drug users were less likely to achieve HIV-1 RNA suppression compared with non-drug users. Adherence as measured by pharmacy refill compliance was not a reliable measure in this subpopulation.
Related Concept Videos
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

